Exit planning is not what you do when you are ready to leave a business. It is what you do three to five years before you want to, so that when the moment arrives — or more often, when the moment is imposed on you — you have built a business that attracts the acquirers, investors, or partners you want, on terms you have prepared for.

In life sciences, where exit paths are limited and buyers are sophisticated, the quality of exit planning is visible in transaction outcomes. Companies that have prepared intentionally tend to achieve better valuations, shorter transaction timelines, and more favorable deal terms than companies for which the exit is an event rather than a destination.

The Exit Path Landscape in Life Sciences

Life sciences companies exit primarily through strategic acquisition, private equity transaction, IPO, or licensing/partnership structures that function as partial exits. Each path has different requirements, different valuation drivers, and different timelines.

Strategic acquisition — sale to a larger company seeking to acquire technology, capabilities, customer base, or market position — is the most common exit for mid-market life sciences companies. Strategic acquirers pay premiums for businesses that fill a specific strategic need: a platform technology they want to own, a market position they want to access, a team with capabilities they would take years to build organically.

Private equity acquisition is increasingly relevant for profitable, durable life sciences services businesses — CDMOs, CROs, consulting and advisory firms, specialty distributors. PE buyers value operating leverage, recurring revenue, and growth platforms. They are financial buyers with a defined investment horizon; the business needs to be positioned for another exit three to seven years later.

IPO remains an option for companies with sufficiently large market opportunity, clinical or commercial proof points, and investor appetite — conditions that are market-dependent and not available to all companies at all times.

Building Toward an Exit

The most important exit planning insight: the actions that maximize exit value are almost entirely the same as the actions that maximize the value of the business as an ongoing enterprise. This means exit planning does not require a separate strategy. It requires executing your business strategy with explicit attention to the dimensions buyers evaluate most intensively.

Buyers of life sciences businesses focus on several specific value dimensions.

Technology and IP quality. Is the core technology defensible? Is the IP estate clear, with no ownership disputes, licensing encumbrances, or freedom-to-operate issues that would create liability for the buyer? Regulatory readiness is part of this: is the regulatory status of the technology clear, and is the pathway to market credible?

Commercial traction. Does the business have customers, and can it demonstrate repeatability? For revenue-generating businesses, buyer attention shifts to customer concentration, contract duration, renewal rates, and the quality of commercial relationships. A business whose revenue is concentrated in one or two customers is a different acquisition risk than a business with diversified, contracted revenue across a broad customer base.

Management depth. Can the business operate without the founder or current CEO? Buyers who acquire businesses in which the value is concentrated in a single individual face significant post-close retention risk. Exit planning that builds genuine management depth — a team capable of operating and growing the business independently — commands a meaningful premium.

Operational systems and quality. Are the processes, systems, and quality management infrastructure documented, auditable, and scalable? For regulated businesses, quality system readiness is not optional. Buyers who discover quality system gaps in diligence will either walk away or price the risk into the transaction.

Timing and the Planning Horizon

Exit planning that begins when the founder has decided to sell is too late. By then, the gaps in management depth, IP cleanliness, customer diversification, and operational infrastructure that buyers will identify in diligence require time to close. Time that is no longer available.

The appropriate planning horizon is three to five years. Within that window, each planning cycle should include a specific question: what are the two or three most material gaps between our current state and the business that our target buyer or investor would pay a premium for — and what is our plan to close them?

This is not about manufacturing a business that looks good in a data room. It is about building a business that is genuinely attractive to the buyers who can value it appropriately.

MKA Point of View

The exits that produce the best outcomes for founders and shareholders are almost never accidents. They are the result of deliberate preparation — knowing who the likely buyers are and what they value, building toward those value dimensions over multiple years, and entering any transaction process from a position of strategic choice rather than operational necessity.

In life sciences specifically, where buyers are sophisticated and diligence is thorough, the quality of preparation is visible. The companies that achieve premium outcomes are the ones that understood their acquisition thesis from the buyer’s perspective before they entered the process.